Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Other Non-Current Assets (2016 - 2025)

VYNE Therapeutics' Other Non-Current Assets history spans 9 years, with the latest figure at $60000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 97.35% year-over-year to $60000.0; the TTM value through Dec 2025 reached $60000.0, down 97.35%, while the annual FY2025 figure was $60000.0, 97.35% down from the prior year.
  • Other Non-Current Assets reached $60000.0 in Q4 2025 per VYNE's latest filing, down from $241000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $3.5 million in Q4 2021 to a low of $54000.0 in Q3 2023.
  • Average Other Non-Current Assets over 5 years is $878055.6, with a median of $423000.0 recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: soared 4605.56% in 2024, then plummeted 97.35% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $3.5 million in 2021, then crashed by 97.15% to $100000.0 in 2022, then plummeted by 46.0% to $54000.0 in 2023, then skyrocketed by 4088.89% to $2.3 million in 2024, then tumbled by 97.35% to $60000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Other Non-Current Assets are $60000.0 (Q4 2025), $241000.0 (Q2 2025), and $1.3 million (Q1 2025).